article thumbnail

An increasing impact of BCMA-targeting biologics in multiple myeloma

Pharmaceutical Technology

This is a result of intensive research efforts that have produced regimens that have prolonged patient survival, most of which are a combination of a proteasome inhibitor + an immunomodulatory drug (ie. billion global sales expected by 2028, followed by Tecvayli with $2.6bn, which would mark a huge win for J&J in the MM space.

article thumbnail

A history of blood cancer treatment

pharmaphorum

After attempts to treat McBean’s symptoms – through cupping, applying leeches for maintenance therapy, and therapeutic phlebotomy – proved unsuccessful, his physician, Dr Thomas Watson, prescribed steel and quinine, while a sample of his urine was sent to chemical pathologist Henry Bence Jones.